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MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated
in numerous cancers and inhibits malignant growth by repressing genes involved in var-
ious oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that
are necessary for basic cancer cell viability as well as cancer stemness, metastasis, and
chemoresistance. This broad anti-oncogenic activity holds the prospect of creating a new
remedy that is effective against tumor heterogeneity.This review focuses on the molecular
mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of
cancer, and a status update of a miR-34 therapy that may be among the ﬁrst miRNAmimics
to reach the clinic.
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INTRODUCTION
Results generated in recent years from genomic and proteomic
approaches have changed our view on cancer. From a disease
previously assumed to be manifested in the alteration of merely
several genes, cancer is in fact genetically very complex. Tumor
cells frequently harbor an array of mutated genes, and each
tumor mass can comprise hundreds of cancer cells with dis-
tinct cancer genotypes (Jones et al., 2008; Parsons et al., 2008;
Gerlinger et al., 2012). As a result, approaches to cancer ther-
apies are shifting to accommodate these new ﬁndings and to
devise more effective and safer remedies. Conventional thera-
pies, still the prevailing form of therapy, are frequently deemed
too toxic or inadequate due to chemoresistance. These treat-
ments are followed or replaced by targeted therapies that intercept
with a known oncogene. At an increasing rate, these targeted
therapies are not solely prescribed based on the histotype but,
rather, on the genetic cancer proﬁle. Thus, those originally
developed for a speciﬁc tumor type can also have activity in
another, yet histologically unrelated cancer type with the same
underlying mutation (Welch and Moore, 2007). However, many
targeted therapies alone are insufﬁciently effective and will have
to be used in combination. This conﬁrms that cancer is the
product of various genetic and epigenetic changes and requires
interference with multiple oncogenic pathways for successful
intervention.
The therapeutic use of miRNAs, a class of non-coding RNAs,
has gained much attention because their mechanisms of action
are in line with our current thinking of cancer as a pathway dis-
ease. miRNAs function as master regulators of the genome by
modulating the expression of tens to hundreds of genes and by
controlling several cellular pathways at once. Certain miRNAs
are frequently deregulated in cancer cells and, consequently, so
are pathways downstream. As a result, a cellular proto-oncogene
can escape miRNA-mediated repression and, thereby, acquire
a gain of function that is independent of mutations to the
proto-oncogene itself (Johnson et al., 2005). A modest number
of miRNAs shows a loss of function in a very broad range of
cancer types, indicating that they play a central role in the reg-
ulation of tumor suppression. Among these are let-7, miR-34,
andmiR-200, all of which are evolutionarily conserved from plant
to man and presumably control basic programs during cellular
proliferation and differentiation. Correcting these deﬁciencies by
miRNA replacement results in an activation of anti-proliferative
and pro-apoptotic pathways, and cancer cell death (Bader et al.,
2010; Wiggins et al., 2010). An obvious patient eligible for
miRNA replacement would be one with miRNA levels that are
lower in the tumor than the normal tissue. However, there is
increasing evidence demonstrating that cancer cells with normal
miRNA expression levels are also susceptible to miRNA treatment
(Wiggins et al., 2010). A plausible explanation for this observation
is the threshold phenomenon – it is likely that oncogenic path-
ways induced by mutations in other genes are controlled, albeit
insufﬁciently counteracted, by the endogenousmiRNA. Increasing
the expression of the miRNA may enhance its antagonizing func-
tion beyond the threshold at which it becomes dominantly tumor
suppressive.
MASTER TUMOR SUPPRESSOR miR-34
One of the challenges that drug developers are facedwith is picking
the right target. This also applies to miRNAs. There are many
miRNAs that are deregulated in cancerous tissues; however, only
few of these induce robust phenotypes in cancer cells, and even
fewer are potent enough to be used as therapeutics. Thus, similar
to other cancer genes, it is possible that miRNAs play distinct roles
in which only a subset function as “drivers” of cancer progression.
In addition, several other miRNAs have been associated with both
www.frontiersin.org July 2012 | Volume 3 | Article 120 | 1
“fgene-03-00120” — 2012/6/29 — 15:59 — page 2 — #2
Bader Development of a miR-34-based cancer therapy
tumor suppressive and oncogenic functions, or assume roles in
diseases outside oncology which makes their practical application
as cancer therapeutics difﬁcult to predict (Valastyan et al., 2009;
Liu et al., 2010).
A miRNA for which the tumor suppressor role is well-deﬁned
is miR-34. Human miR-34 comprises three family members:
miR-34a, miR-34b, and miR-34c. The mature miR-34a sequence
consists of 22 nucleotides and shares 86% homology (19/22 nt)
and 82%homology (18/22 nt) withmiR-34b andmiR-34c, respec-
tively. Both miR-34b and miR-34c are 23 nucleotides in length
and 83% homologous (19/23 nt). Residues identical between all
three family members span across the entire miRNA sequence
and include those in the “seed region,” a stretch of 8 nucleotides
from position 2–9 adjacent to the 5′ terminus that guides the
selection of target mRNAs. Due to this homology, the miR-
34 family members control a similar set of target genes and
appear to be functionally redundant (He et al., 2007). In nor-
mal human tissues, miR-34a is the prevailing family member
(Hsu et al., 2008). In contrast, endogenous miR-34b/c levels
are low in most tissues except lung, ovary, testes, and trachea
(Hsu et al., 2008). The miR-34a gene is located on chromosome
1p36.22, and miR-34b and miR-34c are expressed from a poly-
cistronic transcript encoded on chromosome 11q23.1. Both gene
loci are in regions that have been associated with fragile sites
of the genome that are frequently altered in cancer (Calin et al.,
2004). Hypermethylation of the miR-34 promoters is another
mechanism that can lead to reduced levels of endogenous miR-
34 family members (Lodygin et al., 2008; Lujambio et al., 2008;
Vogt et al., 2011). Thus, genetic and epigenetic mechanisms con-
tribute to a loss of miR-34a expression that has been noted in
a wide range of solid and hematological malignancies, including
cancers of the lung (Bommer et al., 2007; Lodygin et al., 2008;
Gallardo et al., 2009; Wiggins et al., 2010), prostate (Fujita et al.,
2008; Lodygin et al., 2008), breast (Lodygin et al., 2008; Vogt
et al., 2011), pancreas (Chang et al., 2007; Lodygin et al., 2008;
Vogt et al., 2011), colon (Tazawa et al., 2007; Lodygin et al., 2008;
Vogt et al., 2011), kidney (Lodygin et al., 2008; Vogt et al., 2011),
liver (Li et al., 2009; Tryndyak et al., 2009), bladder (Lodygin
et al., 2008), skin (Lodygin et al., 2008), esophagus (Chen et al.,
2011), brain (Welch et al., 2007; Cole et al., 2008; Wei et al., 2008;
Feinberg-Gorenshtein et al., 2009), cervix (Wang et al., 2009; Li
et al., 2010), ovary (Kuo et al., 2009; Corney et al., 2010; Vogt
et al., 2011), urothelium (Vogt et al., 2011), and the lymphoid
system (Mraz et al., 2009; Chim et al., 2010; Craig et al., 2011).
Consistent with this extensive aberrant expression proﬁle, rein-
troducing mimics of miR-34a inhibits numerous cancer cell types
and suggests that miR-34a functions at the core of tumorigenic
processes shared among cancer cells. This anti-oncogenic activity
of miR-34a has been demonstrated in cancer cell types of lung
(Bommer et al., 2007; He et al., 2007; Raver-Shapira et al., 2007;
Tarasov et al., 2007; Sun et al., 2008; Wiggins et al., 2010), liver
(Li et al., 2009), pancreas (Lodygin et al., 2008; Ji et al., 2009),
colon (Chang et al., 2007; He et al., 2007; Tazawa et al., 2007;
Lize et al., 2009), brain (Welch et al., 2007; Cole et al., 2008; Wei
et al., 2008; Luan et al., 2010; Li et al., 2011), skin (Yan et al.,
2009; Greenberg et al., 2011), prostate (Lodygin et al., 2008; Liu
et al., 2011), bone (Tarasov et al., 2007; Yan et al., 2012), ovary
(Corney et al., 2010), as well as lymphoma and leukemia (Asslaber
et al., 2010; Craig et al., 2011).
MOLECULAR MECHANISMS OF miR-34
TUMOR SUPPRESSION
How does miR-34a work? The study of miR-34a-induced pheno-
types is beginning to outline a picture in which miR-34a acts as
a master of tumor suppression (Figure 1). miR-34a can antag-
onize many different oncogenic processes by regulating genes
that function in various cellular pathways (Table 1). A major-
ity of these genes encode well-known proto-oncoproteins that
represent attractive drug targets themselves. It is possible that
the repression of only a few select targets is responsible for the
miR-34a phenotype. Indeed, some of the miR-34a-regulated tran-
scripts have directly been implicated during miR-34a-dependent
tumor suppression (Craig et al., 2011). However, none were able
to fully recapitulate the miR-34a phenotype, suggesting that the
miR-34a function depends on multiple and perhaps the majority
of all targets. The miR-34a-induced change on any of the tar-
geted gene products is moderate and less than 1.23-fold for most
proteins (Kaller et al., 2011). And yet, the collective repression
of a wide range of target genes is likely to a have a signiﬁcant
impact on cellular phenotypes (Selbach et al., 2008). Interest-
ingly, miR-34a targets downregulated on the protein level were
also affected on the mRNA level which suggests that miR-34a
simultaneously affects protein synthesis and mRNA abundance
(Kaller et al., 2011).
A major function attributed to miR-34a is the control of cel-
lular proliferation, cell cycle, and senescence. In cancer cells,
ectopic expression of miR-34a decreases cell doubling rates
(Lodygin et al., 2008; Wiggins et al., 2010), leads to G1/G2 arrest
(He et al., 2007; Lodygin et al., 2008), and transforms cells into
large, ﬂat bodies that stain positive for senescence-associated beta-
galactosidase (He et al., 2007; Tazawa et al., 2007; Lodygin et al.,
2008). miR-34a is upregulated during various forms of senes-
cence, includingquiescence, replicative senescence,H2O2-induced
premature senescence, and senescence induced by an oncogene
(Christoffersen et al., 2009; Maes et al., 2009). In agreement with
these phenotypes are transcriptome and proteome proﬁles gen-
erated in miR-34a overexpressing cells. These results show that
genes differentially expressed function predominantly in the reg-
ulation of the cell cycle (Bommer et al., 2007; Chang et al., 2007;
He et al., 2007). Genes that are downregulated are enriched for
those containing putative miR-34a binding sites, indicating that
FIGURE 1 | Cancer processes counteracted by miR-34.
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Table 1 | Gene products directly repressed by miR-34a.
Cellular process Gene Title Reference
Cell cycle CDK4 Cyclin-dependent kinase 4 (He et al., 2007)
CCNE2 Cyclin E2 (He et al., 2007)
CCND1 Cyclin D1 (Sun et al., 2008)
CDK6 Cyclin-dependent kinase 6 (Sun et al., 2008)
Apoptosis/p53 pathway BCL2 B-cell leukemia/lymphoma 2 (Bommer et al., 2007; Cole et al., 2008)
SIRT1 Sirtuin 1, silent information regulator 1 (Yamakuchi et al., 2008)
YY1 Ying yang 1 transcription factor (Chen et al., 2010; Kaller et al., 2011)
BIRC5 Survivin (Shen et al., 2012)
Wnt signaling /metastasis JAG1 Jagged 1 (Hashimi et al., 2009)
WNT1 Wingless-related MMTV integration site member 1 (Hashimi et al., 2009; Kim et al., 2011)
NOTCH1 Notch homolog 1, translocation-associated (Du et al., 2012)
LEF1 Lymphoid enhancer binding factor 1 (Kaller et al., 2011; Kim et al., 2011)
WNT3 Wingless-type MMTV integration site family member 3 (Kim et al., 2011)
CTNNB1 Beta-catenin (Kim et al., 2011)
LRP6 Low density lipoprotein receptor-related protein 6 (Kim et al., 2011)
MTA2 Metastasis associated 1 family member 2 (Kaller et al., 2011)
TPD52 Tumor protein D52 (Kaller et al., 2011)
AXL AXL receptor tyrosine kinase (Kaller et al., 2011; Mudduluru et al., 2011)
Cancer cell stemness MYCN v-myc myelocytomatosis viral related oncogene N (Cole et al., 2008;Wei et al., 2008)
CD44 Heparan sulfate proteoglycan (Liu et al., 2011)
NANOG NANOG homeobox transcription factor (Choi et al., 2011)
SOX2 SRY (sex determining regionY)-box 2 transcription factor (Choi et al., 2011)
Mitotic signaling MET Met proto-oncogene (hepatocyte growth factor receptor) (He et al., 2007)
MAP2K1 Mitogen-activated protein kinase kinase 1 (MEK1) (Ichimura et al., 2010)
RRAS Related RAS viral (r-ras) oncogene homolog (Kaller et al., 2011)
PDGFRA Platelet-derived growth factor receptor, alpha (Silber et al., 2012)
Oncogenic Transcription E2F3 E2F transcription factor 3 (Welch et al., 2007)
MYB v-myb myeloblastosis viral oncogene homolog (Navarro et al., 2009)
MYC v-myc myelocytomatosis viral oncogene homolog (Christoffersen et al., 2009)
Metabolism ACSL1 Acyl-CoA synthetase long-chain family member 1 (Li et al., 2011)
LDHA Lactate dehydrogenase A (Kaller et al., 2011)
IMPDH IMP (inosine 5′-monophosphate) dehydrogenase (Kim et al., 2012)
several interactions are direct. Transcripts for which the interac-
tions with miR-34a have experimentally been validated include
cyclins D1 and E2, as well as cyclin-dependent kinases 4 and
6. In addition, miR-34a directly represses a series of signaling
molecules that drive cellular proliferation and play roles in the
mitogen-activated protein kinase (MAPK) and phosphoinositide
3-kinase (PI3K) pathways. These are mitogen-activated protein
kinase kinase 1 (MEK1,MAP2K1), R-Ras (RRAS),platelet-derived
growth factor receptor (PDGFRA), and hepatocyte growth factor
receptor (MET).
The functions of miR-34a in the control of the cell cycle are
complemented by those that regulate apoptosis. All miR-34 family
members are transcriptionally induced by p53 and are important
effector molecules in the execution of molecular programs
directed by p53 (Bommer et al., 2007; Chang et al., 2007; He et al.,
2007; Raver-Shapira et al., 2007; Tarasov et al., 2007). miR-34a
represses BCL2 and survivin; however, it is possible that other
mechanisms contribute to the pro-apoptotic functions of miR-
34a (Bommer et al., 2007; Shen et al., 2012). Indeed, miR-34a
can stimulate endogenous p53 activity in a positive feedback-
loop by targeting SIRT1 (silent information regulator 1), a
NAD-dependent deacetylase that deactivates TP53 (tumor pro-
tein 53), and YY1 (yin yang 1), a protein that binds to p53 and
promotes p53 ubiquitination and degradation (Sui et al., 2004;
Yamakuchi et al., 2008; Chen et al., 2010). Thus, it appears that
miR-34a takes advantage of upstream signaling to maintain its
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own expression levels and to activate tumor suppressor path-
ways exclusively regulated by p53. However, the requirement for
p53 in miR-34a-induced tumor suppression remains unknown.
Emerging evidence suggests that endogenous p53 is not a prereq-
uisite formiR-34a tumor suppression –miR-34a transcription can
occur independently of p53, and miR-34a is capable of inhibiting
cancer cells that lack endogenous p53 (Christoffersen et al., 2009;
Wiggins et al., 2010).
A valuable aspect of miR-34a is its ability to inhibit cancer
stem cells. Cancer stem cells, also known as tumor-initiating cells,
are deﬁned as a small fraction of cancer cells that have the abil-
ity to self-renew and to give rise to identical daughter cells (Reya
et al., 2001). As such, cancer stem cells act as the “seed” of the
tumor that has an enhanced propensity to form tumors in the
animal, metastasize and withstand conventional cancer therapy.
Thus, chemoresistance and recurrence are likely due to the pres-
ence of these tumor-initiating cells that ought to be eliminated
for successful patient outcome. For instance, miR-34a levels are
lower in prostate cancer stem cells that express either the CD44
or the CD133 epitope, and in those enriched in the side popula-
tion when compared to the bulk of prostate tumor cells (Liu et al.,
2011). Overexpression of miR-34a, either by transient transfec-
tion or stable genomic integration via a retrovirus, interferes with
sphere formation in soft agar and tumorigenicity in vivo (Liu et al.,
2011). Both are abilities that have speciﬁcally been associated with
the presence of prostate cancer stem cells. miR-34a also inhib-
ited the propagation properties of tumor-initiating cells derived
frompancreatic carcinomaandmedulloblastoma (Ji et al., 2009; de
Antonellis et al., 2011). Thus, the relative amounts of endogenous
miR-34a proportionally decline as cells transform from normal to
cancer and to cancer stem-like cells. This progression appears to
be functionally linked to tumor viability and abolished by miR-34
replacement.
The notion that the modulation of miR-34a abundance has a
direct impact on pluripotency is supported by observations that
implicate miR-34a in somatic cell reprogramming (Choi et al.,
2011). miR-34a prevents cell reprogramming by directly inhibit-
ing pluripotency genes, including NANOG, SOX2, and MYCN
(Choi et al., 2011). Similarly, the ability to inhibit prostate cancer
stem cells was causally linked to miR-34a-dependent repression of
CD44 which may further deﬁne its speciﬁc effects on cancer stem
cells (Liu et al., 2011). Hence, the repression of these pluripotency
genes provides amolecular explanation formiR-34a functions that
govern stemness and differentiation.
Other functions ascribed to miR-34a are during inhibition of
metastasis and chemoresistance. Both may be a consequence of
miR-34a-induced cancer stem cell elimination but may also be
an independent result of miR-34a regulation in non-stem can-
cer cells. The Wnt signaling pathway is intimately involved in
the transition from an epithelial to a mesenchymal state (EMT)
and metastasis. It is subject to miR-34-dependent regulation at
multiple levels. miR-34a and miR-34b/c directly repress the trans-
lation of WNT1 and WNT3, as well as LRP6, a co-receptor
of Frizzled that binds to Wnt ligands (Kim et al., 2011). The
miR-34 family members also represses LEF1 and beta-catenin
(CTNNB1) that function as the primary transcriptional medi-
ators downstream of Wnt. Accordingly, miR-34 interferes with
phenotypes attributed to Wnt signaling such as a block of Wnt-
induced axis duplication during Xenopus development, a decrease
in the tissue-invasive activity of colorectal cancer cells and inhi-
bition of TCF/LEF target genes (Kim et al., 2011). Interestingly,
several of the genes transcriptionally induced by TCF/LEF are
CCND1, MYC, and CD44 that are also independently repressed
by miR-34a. The miRNA also downregulates other pro-metastatic
genes not necessarily linked to the Wnt signaling pathway (MET,
AXL, MTA2; He et al., 2007; Kaller et al., 2011). This corroborates
the concept that the regulatory mechanisms of miRNAs involve
multiple components within a given pathway and across several
others.
The ability to impact multiple cellular pathways may also
suggest that miR-34a can act synergistically with conventional,
cytotoxic therapies. The modes of action of both drug classes
are likely sufﬁciently distinct for the combination to provide an
added beneﬁt. This has experimentally been tested in cancer
cell models of prostate, pancreas, colon, bladder, stomach, and
brain. As shown in Table 2, miR-34a mitigates resistance to taxol-
and platinum-based agents, as well as resistance to a few others.
The effects of the combination in normal tissues are currently
unknown. The mechanisms through which miR-34a exerts its
chemo-sensitizing functions remain ill-deﬁned and require fur-
ther study; and yet, the preliminary data derived from these cell
models may indicate that the utility of a future miR-34a therapeu-
tic can be substantially expanded.
PHARMACOLOGY OF miR-34 IN ANIMAL
MODELS OF CANCER
The biological activity of miR-34a identiﬁed in cell models sug-
gests that it can also suppress tumor growth in vivo. Although
a thorough assessment of miR-34a activity in animals primarily
hinges on the performance of in vivo delivery systems, there are a
few examples that illustrate its therapeutic potential (Table 3).
A common approach to achieve miRNA expression in vivo is
based on vectoral systems that function similarly to those used
for traditional gene therapy (Esquela-Kerscher et al., 2008; Kumar
et al., 2008; Kota et al., 2009; Qiu et al., 2011). These can be
used either on xenografts before transplantation or systemically as
nanoparticles by parenteral administration. Another approach is
in form of nanoparticles that contain∼19–23-nt double-stranded
miRNA mimics and can be administered by intravenous tail
vein injections (Chen et al., 2010; Wiggins et al., 2010). Here,
examples of the systemic delivery mode are discussed in further
detail.
One example of systemic delivery is provided by the intra-
venous delivery of miR-34a in polycationic liposome-hyaluronic
acid nanoparticles that are modiﬁed with a GC4 single-chain anti-
body fragment (scFv; Chen et al., 2010). The antibody moiety
facilitates tumor targeting to human glioma tumor sphere cells as
well as murine B16 melanoma cells. To test the therapeutic util-
ity, the formulation was administered on two consecutive days
(0.3 mg/kg) to mice that had lung metastases induced by the
B16F10melanoma xenograft. Eleven days after the ﬁrst treatment,
the tumor burden was reduced by approximately 50% as assessed
by luminescence imaging of metastatic lesions. In a separate
experiment, miR-34a activity was conﬁrmed by an increase of
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Table 2 | Effects of miR-34a in combination with conventional therapies.
Cancer therapy Cancer type Effects of the miR-34/chemo combination Reference
Camptothecin Prostate Reduced cell viability (Fujita et al., 2008)
Paclitaxel Prostate Attenuates chemoresistance (Kojima et al., 2010)
5-Fluorouracil Colon Attenuates chemoresistance (Akao et al., 2010)
Mitomycin C Brain ∼2-fold lower IC50 than chemo alone (Weeraratne et al., 2010)
Cisplatin Brain ∼2-fold lower IC50 than chemo alone (Weeraratne et al., 2010)
Bladder Reduced clonogenic potential; increased senescence (Vinall et al., 2011)
Pancreas 2.7-fold lower IC50 than chemo alone (Ji et al., 2009)
Stomach∗ 1.8-fold lower IC50 than chemo alone (Ji et al., 2008)
Docetaxel Pancreas 3.2-fold lower IC50 than chemo alone (Ji et al., 2009)
Stomach∗ 2.4-fold lower IC50 than chemo alone (Ji et al., 2008)
Gemcitabine Pancreas 2.6-fold lower IC50 than chemo alone (Ji et al., 2009)
Stomach∗ 2.6-fold lower IC50 than chemo alone (Ji et al., 2008)
Doxorubicin Stomach∗ 2.0-fold lower IC50 than chemo alone (Ji et al., 2008)
*Values were generated in cancer cells with high BCL-2 levels.
Table 3 |Therapeutic activity of miR-34a in animal models of cancer.
Cancer type Mouse tumor model Effects (TGI)∗ Reference
Non-small cell lung cancer s.c. H460 xenograft ∼78%TGI (Wiggins et al., 2010)
s.c. A549 xenograft ∼62%TGI (Wiggins et al., 2010)
KRAS G12D GEMM ∼60%TGI (Trang et al., 2011)
Prostate cancer o.t. PC3 xenograft ∼50%TGI (Liu et al., 2011)
o.t. LAPC9 xenograft ∼20%TGI (Liu et al., 2011)
∼83%TGI on lung metastasis (Liu et al., 2011)
Melanoma metastatic B16 xenograft ∼50%TGI (Chen et al., 2010)
Pancreatic cancer s.c. MiaPaca-2 xenograft ∼62%TGI (Pramanik et al., 2011)
o.t. MiaPaca-2 xenograft ∼68%TGI (Pramanik et al., 2011)
Lymphoma s.c. U2932 xenograft ∼76%TGI (Craig et al., 2012)
*Effects are expressed as percentage TGI in miR-34a-treated animals compared to controls. 100% TGI indicates a complete block of tumor development. TGI was
determined by either calipermeasurements, tumor area, tumorweight, ultra sound, or luminescence of luc-expressing tumor cells. s.c., subcutaneous; o.t., orthotopic;
TGI, tumor growth inhibition.
miR-34a-induced apoptosis and the downregulation of survivin
protein levels in lung metastases.
Pramanik et al. (2011) investigated the therapeutic potential
of miR-34a in subcutaneous and orthotopic pancreas MiaPaca-2
xenografts. miR-34a was delivered systemically using a 100 nm-
lipid-based nanoparticle that contains amiR-34a-encoding vector.
Animals with conﬁrmed tumors were treated three times a
week for three consecutive weeks, and tumor growth was deter-
mined by either caliper measurements or ultra sound. The data
showed that tumors from mice treated with miR-34a were sig-
niﬁcantly smaller and showed signs of necrosis and apoptosis.
Orthotopic tumors also displayed reduced levels of Ki67. In addi-
tion, SIRT1 protein as well as CD44 and ALDH mRNA levels
were reduced in subcutaneous tumor tissues of miR-34a-treated
animals.
A series of experiments were performed with a neutral lipid
emulsion (NLE) that forms particles in the nanometer range
and carry a net charge close to zero. Proof of concept for the
therapeutic utility of the miR-34a/NLE formulation was gener-
ated in subcutaneous H460 and A549 non-small cell lung cancer
xenografts (Wiggins et al., 2010). Mice carrying palpable H460
tumors received a dose of 3 mg/kg via intravenous tail vein injec-
tions every 3 days over a period of 9 days. A549-carrying animals
were dosed at 1 mg/kg every other day for a total of 15 days. In
comparison to controls, tumor growth of miR-34a-treated groups
was inhibited by 78 and 62%, respectively. Both xenografts dis-
played an increase in apoptosis and a reduction in proliferation.
The anti-oncogenic effects were accompanied by an accumulation
of the miR-34a mimic in tumor tissues and a downregulation of
MET, CDK4, and BCL2 protein levels (Wiggins et al., 2010).
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Similar results were obtained in a genetically engineeredmouse
model of lung cancer that is based on the constitutively active
KRAS mutant G12D (Trang et al., 2011). Ten weeks after the acti-
vation of the KRAS-G12Dmutant and the initiation of orthotopic
lung tumors, miR-34a mimics conjugated with NLE were system-
ically introduced every other day for a total of eight injections
at a concentration of 1 mg/kg each time. At sacriﬁce, mice given
a NLE formulation that contained a scrambled negative control
oligonucleotide showed extensive diffuse hyperplasia and adeno-
mas in lungs. In contrast, the lesions observed in miR-34a-treated
animals were few and signiﬁcantly smaller. The remaining tumor
area was only 40% of the overall tumor area that was noted in con-
trols. This result correlated with a signiﬁcant elevation of miR-34a
levels in lung tissue, reduced expression of Ki67 and an increase in
TUNEL-positive cells.
In models of prostate cancer, the efﬁcacy of miR-34a com-
plexed in NLE was demonstrated by Liu et al. (2011). Orthotopic
PC-3 tumors were generated by the surgical implantation of
tumor cells into the dorsal prostate of male NOD/SCID mice
and allowed to grow for 3 weeks. Then, mice were treated every
other day by intravenous tail injections using a dose of 1 mg/kg
per administration. After the ﬁfth dose, mice were sacriﬁced
to determine tumor weights. Tumors were half the weight of
those from control animals (Liu et al., 2011). A similar exper-
imental set-up was used to evaluate miR-34a activity in the
orthotopic LAPC9 tumor xenograft. In these animals, the effect
on the primary tumorwas onlymoderate (20% tumor inhibition).
However, animals in the miR-34a study group greatly beneﬁtted
from signiﬁcantly enhanced survival, most likely due to a sub-
stantial decrease in LAPC9 metastasis to lung and other organs
(Liu et al., 2011).
During the transition from low-grade to high-grade can-
cers, diffuse large B-cell lymphomas frequently show a gain of
MYC function and a concurrent loss of miR-34a. Reintroduc-
tion of miR-34a mimics into cultured lymphoma cells proved
to be more effective in inhibiting lymphoma cells than siRNAs
directed against MYC or FOXP1, another key oncogene in this
type of cancer. This suggests that miR-34a replacement is the
preferred therapeutic modality in this model (Craig et al., 2011).
To explore this experimentally, mice with existing subcutaneous
U2932 lymphoma xenografts were given intravenous injections
of the NLE/miR-34a formulation every other day. Each dose was
equivalent to 1 mg/kg and was repeated eight times over 13 days.
Caliper measurements indicated that miR-34a was able to reduce
tumor growth by 76% which was also reﬂected in tumor weights.
Thus, the data indicate that the therapeutic utility of miR-34a
is not limited to solid tumor types and can also be applied to
hematological malignancies (Craig et al., 2012).
The studies featuring NLE were carried out using double-
strandedmiR-34a mimics in which the active strand is identical to
the endogenous miRNA. Therefore, non-speciﬁc off-target effects
are unlikely because the mimic is expected to repress the same
set of genes that is also regulated by the natural counterpart.
However, the pleiotropism of miRNAs raises concerns about miR-
34a-induced toxicity in normal tissues. It is possible that the
induction of miRNA-regulated pathways that drives the elimina-
tion of cancer cells is also detrimental to normal cells. In discord
with this view, however, the transient transfection of miR-34a had
no noticeable effects in a series of non-cancerous cells (Wiggins
et al., 2010). Likewise, animal studies evaluating the therapeutic
effects of miR-34a formulations failed to detect unwanted side
effects associated with miR-34a. These observations were based
onmouse gross behavior, bodyweights, pathologic examination of
organ morphologies, and blood chemistries indicative of injuries
to liver, kidney, and muscle (Chen et al., 2010; Wiggins et al.,
2010; Pramanik et al., 2011; Craig et al., 2012). In addition, for-
mulated miR-34a mimics did not induce a non-speciﬁc immune
response as assessed by serum cytokine levels in immunocompe-
tent mice (Chen et al., 2010; Wiggins et al., 2010). The average
level of endogenous miR-34a retrieved from most tissues ranges
around 50,000 copies/ng RNA (Hsu et al., 2008). This is equiv-
alent to approximately 500–1,000 copies/cell, given an overall
RNA content of 10–20 pg/cell. Thus, the abundance of endoge-
nous miR-34a in normal tissues suggests that pathways affected
by exogenous miR-34a are already activated or deactivated by
the endogenous miRNA. Therapeutically increasing the miRNA
level may not sufﬁciently change the levels of target genes to
impact the direction of these pathways and normal cell activi-
ties. Experimental evidence to support this hypothesis, however,
is missing.
DEVELOPMENT PROGRESS OF A miR-34 THERAPY
The transition from bench to bedside of a miR-34a-based can-
cer therapy depends on the availability of a clinically relevant
delivery system. Many technologies that were used to establish
proof of concept in the animal are promising candidates but are
not advanced far enough to demonstrate the robustness, scalable
manufacture, and quality controls necessary to support clinical
trials.
To accelerate the path to the clinic, Mirna Therapeutics
screened multiple existing delivery systems that are in pre-clinical
development or have already entered clinical testing with other
oligonucleotide therapeutics. This evaluation encompassed an
assessment of (i) efﬁcacy in appropriate mouse models of cancer,
(ii)miRNAbiodistribution, and (iii) preliminary safety. The deliv-
ery technology with the best combination of efﬁcacy, biodistribu-
tion, and safety was the NOV340 technology (SMARTICLES,
Marina Biotech, Bothell, WA; Mirna Therapeutics Inc., 2011),
an ionizable liposome that forms a particle with a diameter of
∼120 nm. The liposome contains amphoteric lipids that are
cationic at lowpHandneutral or anionic at neutral and higher pH.
The lipids and miRNA mimics are mixed under acidic conditions
to facilitate efﬁcient miRNA encapsulation and liposome forma-
tion. In bioﬂuids with a pH of 7–7.5, the nanoparticles assume a
slightly anionic character that may prevent unwanted interactions
with the negative charge of cellular membranes in the endothe-
lium and other tissues. Since the pH tends to be lower in tumor
areas, the NOV340 particles may become cationic in these areas
and adhere to tumor cells.
The pharmacology of the NOV340/miR-34a formulation was
tested in an orthotopic model of hepatocellular carcinoma. A
model of liver cancer was chosen because (i) the majority of hep-
aticmalignancies presentmutations in pathways that can be antag-
onized by miR-34a (Catalogue of Somatic Mutations in Cancer),
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(ii) miR-34a inhibits human hepatocellular carcinoma cells in cul-
ture (Li et al., 2009), and (iii) efﬁcient NOV340 liposome delivery
to liver. The data showed that treatment of mice carrying exist-
ing tumors led to a signiﬁcant tumor regression and prolonged
survival (Daige et al., 2011; Bader et al., 2012). A histologic exam-
ination of livers revealed that several of the mice appeared to
be tumor-free. This was in stark contrast to mice dosed with
NOV340 particles that were loaded with a scrambled control. The
NOV340/miR-34a-treated animals lacked notable drug-related
side effects as determined by normal organ morphology, blood
chemistries, and serum cytokine levels.
In summary, the data demonstrate the therapeutic utility of
the clinically relevant NOV340/miR-34 formulation in a model
of hepatocellular carcinoma. Mirna Therapeutics has initiated a
preclinical development program to support the manufacture of
cGMPmaterials and the conduction of IND-enabling studies. The
company anticipates initiating clinical trials in 2013 for miR-34
that may be one of the ﬁrst miRNA mimics to reach the clinic.
CLOSING REMARKS
The replacement of miRNAs provides a new therapeutic concept.
It aims to restore a loss of function that has been a largely inacces-
sible approach for drug developers. In addition, it builds on the
regulation of multiple cellular pathways associated with human
disease which appears to be a requirement for successful cancer
therapy. Data generated in the animal suggest that the pharma-
cological delivery of miRNA mimics effectively inhibits tumor
growth and is well-tolerated by normal tissues. This has cleared
the path for a miR-34 therapy to the clinic. The emphasis is now
on safety in higher species and man.
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